UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 15, 2011
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
_____________________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
On
February 15, 2011, Oramed Pharmaceuticals Inc. issued a press release announcing
that its Director of Medical Affairs, Roy Eldor, M.D., was chosen to lecture at
the Fourth International Conference on Advanced Technologies and Treatments for
Diabetes (ATTD) to take place in London, England on February 16-18,
2011.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated by reference herein.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(d)
|
Exhibits
|
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated February 15, 2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
|||
|
Dated:
February 15, 2011
|
|||
|
By:
|
/s/
Nadav Kidron
|
||
|
Nadav
Kidron
|
|||
|
President,
CEO and Director
|
|||
Exhibit
Index
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated February 15,
2011.
|
Oramed
Chosen to Lecture at the Fourth International Conference on
Advanced
Technologies and Treatments for Diabetes in London,
England
JERUSALEM,
Israel – February 15, 2011– Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB)
(www.oramed.com), a developer of alternative drug delivery systems, announced
today that its Director of Medical Affairs, Roy Eldor, M.D., was chosen to
lecture at the Fourth International Conference on Advanced Technologies and
Treatments for Diabetes (ATTD) to take place in London, England on February
16-18, 2011.
The
presentation will be held on February 18, 2011 at 3:30 PM in Hall C at the
Hilton London Metropole. The presentation will be based on the following
abstract: “Continuous monitoring of patients with uncontrolled Type I Diabetes
demonstrated blood glucose reduction upon preprandial administration of
ORMD-0801 insulin capsules”.
For more
information please visit the conference website at: http://www2.kenes.com/attd/info/Pages/GeneralInformation.aspx
About
Oramed Pharmaceuticals
Oramed
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed’s technology is based on over 25 years of
research by top research scientists at Jerusalem’s Hadassah Medical Center.
Oramed’s corporate and R&D headquarters are based in Jerusalem.
For more
information, please visit www.oramed.com.
Forward-looking
statements
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Oramed, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and Oramed’s ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to Oramed’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of Oramed to differ
materially from those expressed or implied in such forward looking statements.
Oramed undertakes no obligation to update or revise any forward-looking
statements.
Company
and Investor Relations Contact:
Oramed
Pharmaceuticals Inc.
Tara
Horn
USA:
+1-646-240-4193
Int’l: +
972-54-334-318
Office: +
972-2-566-0001
Email: tara@oramed.com